Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSALV.L Regulatory News (SALV)

  • There is currently no data for SALV

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results of EGM and return of capital

25 Nov 2014 12:05

RNS Number : 9409X
3Legs Resources plc
25 November 2014
 



For Immediate Release

 

25 November 2014

 

 

3Legs Resources plc

 

Results of Extraordinary General Meeting and return of capital

 

At the Extraordinary General Meeting of 3Legs Resources plc ("3Legs" or the "Company") held today, Resolutions number 1 and 2 contained in the Notice of Extraordinary General Meeting and put to the meeting were duly approved. All the resolutions were decided by way of a poll. Details of the votes cast were as follows.

 

Resolution

In favour

Against

Withheld

1 To approve an Investing Policy

61,894,862

0

0

2 To approve the Capital Return

61,894,862

0

0

 

Immediately following the Extraordinary General Meeting, the board of directors reconsidered the Company's solvency position and confirmed the Capital Return (as defined in the circular sent to shareholders on 7 November 2014) at 18.5 pence per Ordinary Share, equal to approximately £15.9 million in total. Capital return payments of 18.5 pence per Ordinary Share are therefore planned to be made to qualifying shareholders on 2 December 2014.

 

Claim against ConocoPhillips for the return of share of working capital surplus

 

3Legs has decided not to pursue its claim against ConocoPhillips for the return of its 30% share of a working capital surplus accumulated in the joint venture vehicle previously owned by ConocoPhillips jointly with the Company. The value of this claim was $1.64 million net. While 3Legs has been advised that its claim has good grounds, it does not consider that it can justify the significant expense involved in bringing arbitration proceedings, nor the associated risk of delaying a final distribution to shareholders.

 

A further announcement regarding proposals for the final distribution of the Company's remaining cash resources, net of costs, will be published in the near future.

 

 

For further information contact:

 

3Legs Resources plc

Tel:

+44 1624 811 611

Kamlesh Parmar, Chief Executive Officer

Alexander Fraser, Chief Financial Officer

Jefferies Hoare Govett

Tel:

+44 207 029 8000

Simon Hardy

Graham Hertrich

Northland Capital Partners

Tel:

+44 207 382 1100

Matthew Johnson

FTI Consulting

Tel:

+44 203 727 1000

Oliver Winters

Shannon Brushe

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLELFLZFFBFBZ
Date   Source Headline
9th Jan 20202:30 pmRNSCancellation of trading on AIM
20th Dec 201910:30 amRNSCancellation of AIM listing /Potential acquisition
27th Sep 201911:07 amRNSHalf-year Report - Correction
26th Sep 20192:06 pmRNSHalf-year Report
23rd Sep 20193:02 pmRNSAIM Rule 17 Notification
9th Jul 20197:30 amRNSSuspension - SalvaRx Group Plc
9th Jul 20197:30 amRNSSuspension of Trading
28th Jun 201911:26 amRNSFinal Results
31st Jan 20197:00 amRNSChange of Nominated Adviser and Broker
17th Jan 20192:05 pmRNSSecond Price Monitoring Extn
17th Jan 20192:00 pmRNSPrice Monitoring Extension
8th Jan 20194:15 pmRNSResult of AGM and Completion of Disposal
4th Jan 20195:30 pmRNSSalvarx Group
14th Dec 20187:50 amRNSNominated Adviser Status
10th Dec 20187:00 amRNSIssue of US$1 million of Loan Notes by iOx
27th Nov 20187:00 amRNSPosting of Circular and Notice of AGM
21st Nov 20181:00 pmRNSTransaction Update
6th Nov 20187:00 amRNSDirector/PDMR Dealing
22nd Oct 20189:47 amRNSIntensity Therapeutics Update
9th Oct 20187:00 amRNSExercise of Warrants
27th Sep 20187:00 amRNSHalf-year Report
28th Aug 20185:40 pmRNSUpdate re proposed disposal and demerger
14th Aug 20187:00 amRNSProposed disposal of interest in SalvaRx Limited
1st Aug 20184:40 pmRNSSecond Price Monitoring Extn
1st Aug 20184:35 pmRNSPrice Monitoring Extension
23rd Jul 20181:17 pmRNSDelay in iOx development programme
28th Jun 20187:00 amRNSFinal Results
26th Jun 20187:00 amRNSRelated Party Loan of US$1 million
8th Mar 201812:00 pmRNSDrug Pipeline Progress and iOx Loan Note Issue
30th Oct 20174:40 pmRNSSecond Price Monitoring Extn
30th Oct 20174:35 pmRNSPrice Monitoring Extension
23rd Oct 20177:00 amRNSSubscriptions for SalvaRx Ltd Loan Facility
27th Sep 20179:00 amRNSHalf-year Report
25th Sep 20178:00 amRNSFormation of Saugatuck Therapeutics
1st Aug 20173:30 pmRNSHolding(s) in Company
1st Aug 20173:30 pmRNSHolding(s) in Company
31st Jul 20171:45 pmRNSResult of AGM
5th Jul 20173:03 pmRNSNotice of AGM
30th Jun 20178:34 amRNSFinal Results
30th May 201712:45 pmRNSIntensity Therapeutics Treats First Patient
20th Mar 20177:00 amRNSInvestment in Rift Biotherapeutics
2nd Mar 20177:00 amRNSRestructuring, Loan Conversion and Loan Facility
28th Feb 20177:00 amRNSInvestment in Nekonal
2nd Feb 20174:37 pmRNSIntensity Therapeutics
3rd Oct 20164:40 pmRNSSecond Price Monitoring Extn
3rd Oct 20164:35 pmRNSPrice Monitoring Extension
14th Sep 20167:00 amRNSCorporate Video
13th Sep 20167:00 amRNSHalf-year Report
22nd Aug 20167:00 amRNSDrug Pipeline Progress including Patent Grants
4th Aug 20162:05 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.